caa a22 4500 605490708 CHVBK 20210128100506.0 cr unu---uuuuu 210128e20151201xx s 000 0 eng 10.1007/s10147-015-0836-1 doi (NATIONALLICENCE)springer-10.1007/s10147-015-0836-1 Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study [Elektronische Daten] [Séna Yossi, Benjamin Linot, Guillaume Peyraga, Renaud Breheret, Laurent Laccourreye, Olivier Capitain] Abstract : Background: Docetaxel-cisplatin and 5-fluorouracil (TPF) chemotherapy (days 1-21) represents a standard but toxic regimen for advanced head and neck cancer (HNC). We report a retrospective monocentric study evaluating the safety and the efficacy of a dose-dense modified TPF (mTPF) regimen (days 1-14) in patients with stage III-IV HNC. Methods: Thirty-seven patients retrospectively included from May 2011 to May 2014 were treated with a bimonthly dose-dense mTPF regimen (40mg/m2 docetaxel, 40mg/m2 cisplatin or AUC2 carboplatin, folinic acid 400mg/m2 for 2h, bolus 5-FU 400mg/m2 for 10min and 5-FU 1,000mg/m2/day) by continuous infusion over 46h). Results: Chemotherapy was used as induction or palliative treatment in 12 and 25 patients, respectively, with a median age of 60 years (range 46−83). Median follow-up time was 7.4months (2.53-16.7months). There was no intestinal toxicity in 25 patients (68%). Grade 3-4 hematological toxicity was noticed for 5 (13.5%) patients. Granulocyte-colony stimulating factor was used as primary prophylaxis in 30 patients (81%). After at least 4 delivered cycles, complete responses, partial responses and stable diseases were reported in 5 (15%), 13 (39%) and 5 (15%) of the 33 evaluable patients, respectively, yielding an objective response rate of 54.5% (39% for palliative chemotherapy and 90% for induction chemotherapy). Conclusion: Dose-dense mTPF (days 1-14) is safe and seems to be as effective as TPF (days 1-21). Future prospective trials are required to confirm our results. Japan Society of Clinical Oncology, 2015 5-fluorouracil nationallicence Docetaxel nationallicence Cisplatin nationallicence Head and neck cancer nationallicence Dose-dense chemotherapy nationallicence Quality of life nationallicence Yossi Séna Department of Oncopharmacology-Pharmacogenetics, Integrated Center of Oncology (ICO) Paul Papin, 2 rue Moll, 49033, Angers Cedex 9, France aut Linot Benjamin Department of Oncopharmacology-Pharmacogenetics, Integrated Center of Oncology (ICO) Paul Papin, 2 rue Moll, 49033, Angers Cedex 9, France aut Peyraga Guillaume Department of Oncopharmacology-Pharmacogenetics, Integrated Center of Oncology (ICO) Paul Papin, 2 rue Moll, 49033, Angers Cedex 9, France aut Breheret Renaud Head and Neck Surgery Department, Centre Hospitalier Universitaire, 4 Rue Larrey, 49100, Angers, France aut Laccourreye Laurent Head and Neck Surgery Department, Centre Hospitalier Universitaire, 4 Rue Larrey, 49100, Angers, France aut Capitain Olivier Department of Oncopharmacology-Pharmacogenetics, Integrated Center of Oncology (ICO) Paul Papin, 2 rue Moll, 49033, Angers Cedex 9, France aut International Journal of Clinical Oncology Springer Japan 20/6(2015-12-01), 1086-1092 1341-9625 20:6<1086 2015 20 10147 https://doi.org/10.1007/s10147-015-0836-1 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-015-0836-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Yossi Séna Department of Oncopharmacology-Pharmacogenetics, Integrated Center of Oncology (ICO) Paul Papin, 2 rue Moll, 49033, Angers Cedex 9, France aut NATIONALLICENCE 700 1- Linot Benjamin Department of Oncopharmacology-Pharmacogenetics, Integrated Center of Oncology (ICO) Paul Papin, 2 rue Moll, 49033, Angers Cedex 9, France aut NATIONALLICENCE 700 1- Peyraga Guillaume Department of Oncopharmacology-Pharmacogenetics, Integrated Center of Oncology (ICO) Paul Papin, 2 rue Moll, 49033, Angers Cedex 9, France aut NATIONALLICENCE 700 1- Breheret Renaud Head and Neck Surgery Department, Centre Hospitalier Universitaire, 4 Rue Larrey, 49100, Angers, France aut NATIONALLICENCE 700 1- Laccourreye Laurent Head and Neck Surgery Department, Centre Hospitalier Universitaire, 4 Rue Larrey, 49100, Angers, France aut NATIONALLICENCE 700 1- Capitain Olivier Department of Oncopharmacology-Pharmacogenetics, Integrated Center of Oncology (ICO) Paul Papin, 2 rue Moll, 49033, Angers Cedex 9, France aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/6(2015-12-01), 1086-1092 1341-9625 20:6<1086 2015 20 10147